Study reveals new method of preparing imaging agents
Dr. Benjamin Rotstein and collaborators unveil an operationally simple method to prepare carbon isotope-labeled versions of drugs and diagnostics
Dr. Benjamin Rotstein and collaborators unveil an operationally simple method to prepare carbon isotope-labeled versions of drugs and diagnostics.
The development of new pharmaceuticals relies on the ability of scientists to design elegantly specific drugs for targeted clinical trials. And the isotopic labeling of drug candidates in research labs is crucial in this overall effort.
In a new study, Dr. Benjamin Rotstein’s lab at the uOttawa Faculty of Medicine has collaborated with colleagues to unveil an operationally simple method to prepare carbon isotope-labeled versions of drugs and diagnostics. They developed a method to exchange a single atom in amino acids – building blocks of proteins that are also used to prepare molecules – for its isotope.
“This is really important in drug development because we want to know where the drug goes in the body, how is it metabolized and eliminated so we can plan appropriate dosing and toxicity studies,” says Dr. Rotstein, an associate professor in the Faculty of Medicine’s Department of Biochemistry, Microbiology and Immunology.
The work was described in a paper in Nature Chemistry, a high-impact journal that also published a separate article on the study in which two Danish scientists at Aarhus University described the team’s methods as “important to the field.”
Dr. Rotstein’s lab initially designed their experiments to work like a catalyst that our bodies use: pyridoxal phosphate, which removes the carboxylic acid from amino acids and is the active form of vitamin B-6. But he says they wanted to make it run in reverse, and it turned out the mechanism was a little different than they initially expected.
“We’re actually adding carbon dioxide, then removing the acid. So it’s a different mechanism that allows us to consider even better catalysts and expanding the scope further beyond amino acids,” he says.
The research was done in collaboration with University of Alberta colleagues and chemists at Sanofi, the French pharmaceutical company. Dr. Rotstein’s lab did the carbon-11 studies and worked with these collaborators to unveil the mechanism of the reaction. His lab uses carbon-11 because it’s radioactive in a way that works well for medical imaging.
What are the next steps for his uOttawa lab? Dr. Rotstein and his team are now studying how to make the reaction produce only one “mirror-image” version of amino acids so that researchers won’t need to separate them after the fact.
He says they are especially excited about using carbon-11 amino acids to measure the rate that our bodies are producing proteins because this can be an indicator of disease.
“We’re also using these in imaging studies now to learn about metabolism and protein synthesis rates in different tissues,” says Dr. Rotstein, who is also director of the Molecular Imaging Probes and Radiochemistry Laboratory at the University of Ottawa Heart Institute.
- isotope labelling
- drug development
- pyridoxal phosphate
- imaging agents
- 1Can the AI driving ChatGPT help to detect early signs of Alzheimer's disease?
- 2Simple nasal swab can provide early warning of emerging viruses
- 3Diagnosing cancer in minutes
- 4Holes in T cells
- 5A mobile breakthrough for water environment monitoring
- 6Molecular archeology: 1200-year-old DNA sequences from Madagascar lead to the discovery of an extinct tortoise
- 7Sartorius with clear double-digit growth in fiscal 2022
- 8Bruker Announces Acquisition of ACQUIFER Imaging GmbH
- 9How old is your brain, really?
- 10The architecture of shattered genomes
- Study reveals new method of preparing imaging agents
- Identifying toxic materials in water with machine learning
- Scientists unveil world’s first molecular-level analysis of Omicron spike protein
- COVID-19 : Measuring viral RNA to predict which patients will die
- New prognostic biomarkers and cancer-driving genes found in the dark matter of the cancer genome